[HTML][HTML] SARS-CoV-2 variants, vaccines, and host immunity
P Mistry, F Barmania, J Mellet, K Peta… - Frontiers in …, 2022 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
[HTML][HTML] T cells: warriors of SARS-CoV-2 infection
P de Candia, F Prattichizzo, S Garavelli… - Trends in …, 2021 - cell.com
Severe infection with severe acute respiratory syndrome coronavirus (SARS-CoV)-2 is
characterized by massive cytokine release and T cell loss. The exaggerated host immune …
characterized by massive cytokine release and T cell loss. The exaggerated host immune …
[HTML][HTML] Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome
MAF Queiroz, PFM Neves, SS Lima… - Frontiers in cellular …, 2022 - frontiersin.org
The duration and severity of COVID-19 are related to age, comorbidities, and cytokine
synthesis. This study evaluated the impact of these factors on patients with clinical …
synthesis. This study evaluated the impact of these factors on patients with clinical …
A global picture: therapeutic perspectives for COVID-19
VP Chavda, C Kapadia, S Soni, R Prajapati… - …, 2022 - Taylor & Francis
The COVID-19 pandemic is a lethal virus outbreak by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), which has severely affected human lives and the global …
coronavirus-2 (SARS-CoV-2), which has severely affected human lives and the global …
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial
In this study, the therapeutic efficacy of quercetin in combination with remdesivir and
favipiravir, were evaluated in severe hospitalized COVID-19 patients. Our main objective …
favipiravir, were evaluated in severe hospitalized COVID-19 patients. Our main objective …
Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets
K Sriram, PA Insel - Physiological reviews, 2021 - journals.physiology.org
Evolving information has identified disease mechanisms and dysregulation of host biology
that might be targeted therapeutically in coronavirus disease 2019 (COVID-19). Thrombosis …
that might be targeted therapeutically in coronavirus disease 2019 (COVID-19). Thrombosis …
[HTML][HTML] Herbal remedies, nutraceuticals, and dietary supplements for COVID-19 management: an update
Currently, the world is facing a Coronavirus pandemic with a grave deficiency of specific
therapy for Coronavirus Disease (COVID-19). Moreover, scientists attempt to discover the …
therapy for Coronavirus Disease (COVID-19). Moreover, scientists attempt to discover the …
OMICRON: Virology, immunopathogenesis, and laboratory diagnosis
M Bazargan, R Elahi… - The Journal of Gene …, 2022 - Wiley Online Library
Since its emersion, coronavirus disease 2019 (COVID‐19) has been a significant global
dilemma. Several mutations in the severe acute respiratory virus (SARS‐Co‐2) genome has …
dilemma. Several mutations in the severe acute respiratory virus (SARS‐Co‐2) genome has …
[HTML][HTML] Withania somnifera (L.) Dunal: opportunity for clinical repurposing in COVID-19 management
A Saggam, K Limgaokar, S Borse… - Frontiers in …, 2021 - frontiersin.org
As the COVID-19 pandemic is progressing, the therapeutic gaps in conventional
management have highlighted the need for the integration of traditional knowledge systems …
management have highlighted the need for the integration of traditional knowledge systems …
Possible cancer-causing capacity of COVID-19: Is SARS-CoV-2 an oncogenic agent?
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has shown diverse life-
threatening effects, most of which are considered short-term. In addition to its short-term …
threatening effects, most of which are considered short-term. In addition to its short-term …